# Trastuzumab Emtansine

## Kadcyla inj 100mg (sample)

*藥物代碼*：IKAD0

*給藥途徑*：I

*用法用量*：

*Do NOT substitute trastuzumab emtansine (Kadcyla(TM)) for trastuzumab (Herceptin(R))

Metastatic breast cancer, HER2 overexpression, monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy: trastuzumab emtansine (Kadcyla(TM)), 3.6 mg/kg IV infusion every 3 weeks (21-day cycle); infuse first infusion over 90 minutes and subsequent infusions over 30 minutes; do not exceed 3.6 mg/kg dose; if a dose must be delayed or missed, administer as soon as possible without waiting until the next planned cycle; adjust to maintain a 3-week interval between doses.

## KADCYLA inj 160mg (sample)

*藥物代碼*：IKAD00

*給藥途徑*：I

*用法用量*：

*Do NOT substitute trastuzumab emtansine (Kadcyla(TM)) for trastuzumab (Herceptin(R))

Metastatic breast cancer, HER2 overexpression, monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy: trastuzumab emtansine (Kadcyla(TM)), 3.6 mg/kg IV infusion every 3 weeks (21-day cycle); infuse first infusion over 90 minutes and subsequent infusions over 30 minutes; do not exceed 3.6 mg/kg dose; if a dose must be delayed or missed, administer as soon as possible without waiting until the next planned cycle; adjust to maintain a 3-week interval between doses.

## Kadcyla inj 100mg

*藥物代碼*：IKAD1

*給藥途徑*：I

*用法用量*：

*Do NOT substitute trastuzumab emtansine (Kadcyla(TM)) for trastuzumab (Herceptin(R))

Metastatic breast cancer, HER2 overexpression, monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy: trastuzumab emtansine (Kadcyla(TM)), 3.6 mg/kg IV infusion every 3 weeks (21-day cycle); infuse first infusion over 90 minutes and subsequent infusions over 30 minutes; do not exceed 3.6 mg/kg dose; if a dose must be delayed or missed, administer as soon as possible without waiting until the next planned cycle; adjust to maintain a 3-week interval between doses.

## KADCYLA inj 160mg

*藥物代碼*：IKAD6

*給藥途徑*：I

*用法用量*：

*Do NOT substitute trastuzumab emtansine (Kadcyla(TM)) for trastuzumab (Herceptin(R))

Metastatic breast cancer, HER2 overexpression, monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy: trastuzumab emtansine (Kadcyla(TM)), 3.6 mg/kg IV infusion every 3 weeks (21-day cycle); infuse first infusion over 90 minutes and subsequent infusions over 30 minutes; do not exceed 3.6 mg/kg dose; if a dose must be delayed or missed, administer as soon as possible without waiting until the next planned cycle; adjust to maintain a 3-week interval between doses.

